Valuation: Syntara Limited

Market Cap 37.3M 26.23M 23.43M 21.64M 19.61M 36.69M 2.49B 260M 103M 1.3B 98.45M 96.35M 4.11B P/E 2027 *
-3.8x
P/E 2028 * -6.33x
Enterprise Value 4.5M 3.16M 2.82M 2.61M 2.36M 4.42M 300M 31.4M 12.43M 157M 11.87M 11.62M 496M EV / Sales 2027 *
-
EV / Sales 2028 * 2.22x
Free-Float
72.69%
Yield 2027 *
-
Yield 2028 * -
1 day-5.00%
Current month-13.64%
1 month-17.39%
3 months-13.64%
6 months-40.62%
Current year-45.71%
1 week 0.02
Extreme 0.019
0.02
1 month 0.02
Extreme 0.019
0.03
Current year 0.02
Extreme 0.019
0.04
1 year 0.02
Extreme 0.019
0.04
3 years 0.01
Extreme 0.014
0.1
5 years 0.01
Extreme 0.014
0.13
10 years 0.01
Extreme 0.014
0.37
Manager TitleAgeSince
Chief Executive Officer 64 12/03/2013
Chief Tech/Sci/R&D Officer - 01/07/2022
Chief Tech/Sci/R&D Officer - 01/10/2023
Director TitleAgeSince
Director/Board Member 64 12/03/2013
Chairman 68 03/10/2023
Director/Board Member - 16/12/2022
Date Insider Type Main position Quantity % Market Cap. Importance
13/03/25 Buy

Director

9,753,442 0.6008%
24/09/24 Buy

Director

53,571,429 4.1513%
12/08/21 Expiration

Chief Executive Officer

471,000 0.1040%
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%0.00%-38.71%-42.42% 26.23M
+2.41%+0.29%+39.41%+73.38% 64.69B
-0.15%+7.50%+11.42%+75.22% 54.78B
+0.57%+4.60%+7.71%+100.57% 53.49B
+0.37%+4.67%+26.68%+54.16% 45.98B
-1.21%+2.32%+21.50%+126.83% 42.94B
-0.37%+5.07%+243.23%+834.48% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
-0.17%-8.77%+22.48%+2.61% 23.97B
-0.38%+5.68%+38.39%+29.86% 23.67B
Average -0.40%+1.67%+39.02%+130.32% 38.31B
Weighted average by Cap. +0.30%+2.73%+45.77%+151.44%

Financials

2027 *2028 *
Net sales - 5.5M 3.87M 3.45M 3.19M 2.89M 5.41M 367M 38.4M 15.2M 192M 14.52M 14.21M 607M
Net income -31.85M -22.4M -20M -18.48M -16.75M -31.33M -2.13B -222M -88.04M -1.11B -84.07M -82.28M -3.51B -31.5M -22.16M -19.78M -18.28M -16.56M -30.99M -2.1B -220M -87.08M -1.1B -83.15M -81.38M -3.47B
Net Debt -32.8M -23.07M -20.6M -19.03M -17.25M -32.27M -2.19B -229M -90.67M -1.15B -86.58M -84.74M -3.62B -25.1M -17.65M -15.76M -14.56M -13.2M -24.69M -1.68B -175M -69.38M -878M -66.25M -64.84M -2.77B
Projected Income Statement - Annual - Syntara Limited
Logo Syntara Limited
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing topical pan-LOX inhibitors in scar revision, keloid scarring and scar prevention post-surgery. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
Employees
-
Date Price Change Volume
23/10/26 A$0.0190 -5.00% 726,890
22/10/26 A$0.0200 0.00% 243,234
21/10/26 A$0.0200 +2.56% 41,301
20/10/26 A$0.0195 -2.50% 284,084
19/10/26 A$0.0200 +5.26% 280,610
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Syntara Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0190AUD
Average target price
0.1050AUD
Spread / Average Target
+452.63%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Syntara Limited